Aligos Therapeutics ALGS Cash Flow Statement (2019-2026)

NASDAQ ALGS
$2.10 +0.12 (+6.06%)
At close: Nov 13, 2026 · 4:00 PM EST
Reported Financials

Aligos Therapeutics Quarterly Cash Flow Statement

Periods 29 quarters
Latest Sep 2026

Aligos Therapeutics reported cash from operations of $1.45M and free cash flow of $1.58M for the quarter ended Sep 2026, up 106.0% year over year. This cash flow statement covers 29 quarters of results from Sep 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-37.71M-35.62M-19.92M-18.62M-21.89M-22.96M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M-21.86M
Depreciation and DepletionDep. & Depletion
0.72M0.70M0.60M0.50M0.51M0.50M0.40M0.30M0.40M0.30M0.30M0.30M0.23M0.20M0.30M0.20M0.23M0.35M0.30M0.30M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.72M0.70M0.60M0.50M0.51M0.50M0.40M0.30M0.40M0.30M0.30M0.30M0.23M0.20M0.30M0.20M0.23M0.35M0.30M0.30M
Share-based CompensationStock Comp.
3.65M3.79M3.99M3.49M3.42M3.66M3.20M3.21M2.58M0.15M0.14M2.04M1.71M0.05M0.11M1.47M1.46M0.09M0.14M1.28M
Gains from Investment SecuritiesGains Investment
14.37M-30.48M
Asset Writedowns and ImpairmentWritedown
0.70M
Other non-cash itemsOther Non-Cash
0.29M0.31M0.32M0.37M0.38M0.39M2.98M-4.21M2.55M14.77M-30.13M0.52M62.56M-61.18M-1.09M4.68M-0.72M-2.89M-2.50M0.24M
Change in Working Capital
Change in Account PayablesChange Payables
0.40M0.74M-0.99M0.17M1.81M-1.92M0.42M-0.30M-0.42M0.33M3.98M-4.08M-0.17M1.73M-0.40M0.75M-0.67M3.66M-1.21M-3.22M
Change in Accrued ExpensesChange Accrued Exp.
3.88M-6.07M-6.35M0.90M2.39M-0.94M-1.27M-1.46M4.58M-4.80M0.02M2.10M1.29M-4.77M1.41M1.40M-0.08M-1.54M6.71M-3.55M
Change in Other Operating AssetsOther Assets Change
7.81M-3.90M-1.98M-0.57M0.57M-2.09M-2.17M0.78M1.18M-0.20M-0.14M-0.17M0.30M0.15M-0.34M-0.59M0.68M-0.32M-0.62M-1.47M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.92M12.39M-4.60M-4.48M-2.76M-2.91M-0.68M-3.67M-3.27M-1.22M-0.03M-1.37M-1.22M-0.65M-0.42M-1.21M-0.99M-0.88M-0.83M-0.95M
Other Working Capital ChangesOther WC Changes
-8.73M16.29M-2.63M-3.91M-3.33M-0.82M1.49M-4.45M-4.45M-1.02M0.11M-1.20M-1.51M-0.80M-0.08M-0.62M-1.67M-0.56M-0.21M0.53M
Cash from OperationsCash from Ops.
-37.48M-20.43M-25.04M-17.14M-16.78M-22.39M-13.62M-20.34M-22.66M-22.75M-19.49M-20.10M-18.40M-20.91M-15.50M-24.35M-21.75M-23.13M-24.95M1.45M
Investing Activities
Capital ExpendituresCapex
0.34M0.52M0.33M0.00M0.09M0.01M-0.02M0.03M-0.07M-0.01M-0.03M0.23M-0.04M-0.11M-0.19M-0.09M-0.07M0.00M-0.13M
Change in Property, Plant and EquipmentChange in PP&E
-0.34M-0.52M-0.33M0.00M-0.09M-0.01M0.02M-0.03M0.07M0.01M0.03M-0.23M0.04M0.11M0.19M0.09M0.07M0.00M0.13M
Purchase of InvestmentsInvestments Purchased
16.14M59.89M14.89M4.96M24.53M0.01M0.00M88.57M19.58M64.02M39.31M22.12M39.43M
Sale and Maturity of InvestmentsInvestments Sold
-13.11M-0.25M5.49M37.45M-42.75M20.00M25.00M0.01M-44.92M-0.07M0.02M30.08M19.98M20.00M70.00M37.50M35.00M25.00M
Other Investing Activities (as filed)Other investing (as filed)
-0.49M1.56M-1.54M0.06M0.04M0.40M-0.36M0.03M0.00M0.22M-0.15M0.04M
Cash from Investing ActivitiesCash from Investing
-16.48M-60.40M-9.98M32.48M11.60M19.99M25.00M-0.01M-0.01M-88.64M39.99M10.40M19.97M-44.07M-39.42M47.68M-2.02M34.93M25.00M-0.13M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
0.02M0.03M0.03M0.03M-0.03M0.02M0.05M0.02M0.00M0.02M0.02M0.01M0.04M0.01M0.00M0.06M0.02M0.01M
Net Long-Term Debt Issued (Repaid)Net LT Debt
-0.02M-0.03M-0.03M-0.03M0.03M-0.02M-0.05M-0.02M0.00M-0.02M-0.02M-0.01M-0.04M-0.01M0.00M-0.06M-0.02M-0.01M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.02M-0.03M-0.03M-0.03M0.03M-0.02M-0.05M-0.02M0.00M-0.02M-0.02M-0.01M-0.04M-0.01M0.00M-0.06M-0.02M-0.01M
Change in Capital Stock
Common Stock IssuedStock Issued
0.72M0.01M0.11M0.01M0.07M0.02M0.46M0.09M0.14M101.74M-101.56M0.12M
Net Shares Issued and RepurchasedNet Shares Issued
0.72M0.01M0.11M0.01M0.07M0.02M0.46M0.09M0.14M101.74M-101.56M0.12M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.72M0.01M0.11M0.01M0.07M0.02M0.46M0.09M0.14M101.74M-101.56M0.12M
Other financing activities (as filed)
-0.15M-0.03M-0.03M-0.03M0.03M-0.02M-0.05M-0.02M0.00M-0.02M-0.02M-0.01M-0.04M-0.01M0.00M-0.06M-0.02M-0.01M
Cash from Financing ActivitiesCash from Financing
0.55M-0.02M0.08M-0.02M0.12M0.00M0.41M-0.02M87.94M-0.02M0.28M0.00M0.10M101.74M-0.18M-0.05M0.12M-0.06M0.22M-0.01M
Additional items
Change in Cash
-53.41M-80.86M-34.93M15.33M-5.06M-2.40M11.80M-20.37M65.27M-111.41M20.78M-9.71M1.67M36.77M-55.10M23.29M-23.64M11.74M0.27M1.32M
Ending Cash Balance
186.98M106.12M71.19M86.52M81.46M79.07M90.87M70.50M135.77M24.37M45.15M35.44M37.11M73.87M18.77M42.06M18.41M30.15M30.42M31.74M
Free Cash FlowFCF
-37.82M-20.95M-25.37M-17.14M-16.87M-22.39M-13.62M-20.32M-22.69M-22.68M-19.49M-20.08M-18.64M-20.87M-15.40M-24.15M-21.65M-23.06M-24.95M1.58M
Net Cash FlowNCF
-53.41M-80.86M-34.93M15.33M-5.06M-2.40M11.80M-20.37M65.27M-111.41M20.78M-9.71M1.67M36.77M-55.10M23.29M-23.64M11.74M0.27M1.32M
Interest Paid

Aligos Therapeutics Cash Flow Statement API

Pull Aligos Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ALGS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY